New data on Eli Lilly's experimental Alzheimer's drug backs a hotly debated scientific theory, but shows mixed benefits for patients

New data on Eli Lilly's experimental Alzheimer's drug backs a hotly debated scientific theory, but shows mixed benefits for patients

Business Insider

Published

Eli Lilly's treatment reduced a harmful substance in the brains of patients with Alzheimer's disease and slowed their rate of cognitive decline.

Full Article